Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the filing of a provisional patent application covering a ...
Option agreement Supports Vector's Entry into the $80.8 Billion Peptide Market with 22 Novel Pharmaceutical-Grade Formulations MEQUON, Wis., May 13, 2026 /PRNewswire/ -- Vector Science & Therapeutics ...
The Company's stock option plan is a 10% rolling plan. As of the date hereof, a total of 6,556,610 common shares of the Company are reserved for issuance under the Company's stock option plan, with ...
Former Wisconsin Governor and U.S. Secretary of Health and Human Services Brings Extensive Healthcare Leadership to Pioneer of Transdermal Drug Delivery Technology MEQUON, Wis., April 30, 2026 ...
MEQUON, Wis., June 8, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the appointment of Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board ...
Agreement provides Vector access to FDA-registered, cGMP facility and supports development of 24 novel shelf-stable peptide formulations targeting the $80.8 billion peptide market MEQUON, Wis., May 11 ...
14-Year MLB Veteran and 2016 World Series Champion Joins Valor, Vector's Athlete Platform, to Make Sure the Next Generation Plays Longer and Hurts Less MEQUON, Wis., June 12, 2026 /PRNewswire/ -- ...
Proprietary Magnetic Patch System Delivers Regenerative Peptides to Targeted Tissue Without Injection, with Built-In Confirmation of Successful Delivery MEQUON, Wis., June 30, 2026 /PRNewswire/ -- ...
Option agreement Supports Vector's Entry into the $80.8 Billion Peptide Market with 22 Novel Pharmaceutical-Grade Formulations FDA-Registered, cGMP Manufacturing-- MPP operates a modern 35,000 sq. ft.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results